Christopher J Kane

List of Publications by Year
in descending order

258 papers	12,340 citations	26567 56 h-index	32761 100 g-index
260 all docs	260 docs citations	260 times ranked	11569 citing authors

#	Article	IF	Citations
1	Experience with 10Âyears of a robotic surgery program at an Academic Medical Center. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 1950-1960.	1.3	11
2	Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. Journal of Urology, 2022, 207, 592-600.	0.2	6
3	Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. Cancer, 2022, 128, 770-777.	2.0	23
4	Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids. International Journal of Molecular Sciences, 2022, 23, 3203.	1.8	7
5	Impact of age on treatment response in men with prostate cancer treated with radiotherapy. BJUI Compass, 2022, 3, 243-250.	0.7	2
6	Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate, 2022, 82, 366-372.	1.2	3
7	Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. Urology, 2021, 149, 181-186.	0.5	3
8	Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCHÂdatabase. Cancer Causes and Control, 2021, 32, 189-197.	0.8	1
9	Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. Oncology, 2021, 35, 166-168.	0.4	2
10	Safety of concomitant therapy with radiumâ€223 and abiraterone or enzalutamide in a realâ€world population. Prostate, 2021, 81, 390-397.	1.2	5
11	The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical Prostatectomy. Urology Practice, 2021, 8, 238-245.	0.2	1
12	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. JNCI Cancer Spectrum, 2021, 5, pkab023.	1.4	13
13	Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. European Urology, 2021, 80, 20-31.	0.9	33
14	A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Science Advances, 2021, 7, .	4.7	20
15	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	3.4	49
16	Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. International Journal of Urology, 2020, 27, 851-857.	0.5	6
17	Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance. JAMA - Journal of the American Medical Association, 2020, 324, 1747.	3.8	43
18	Race does not predict skeletalâ€related events and allâ€cause mortality in men with castrationâ€resistant prostate cancer. Cancer, 2020, 126, 3274-3280.	2.0	3

#	Article	IF	Citations
19	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. Journal of Translational Medicine, 2020, 18, 214.	1.8	23
20	African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. Prostate Cancer and Prostatic Diseases, 2020, 23, 581-588.	2.0	4
21	Obesity, race, and longâ€term prostate cancer outcomes. Cancer, 2020, 126, 3733-3741.	2.0	32
22	Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer and Prostatic Diseases, 2020, 23, 689-695.	2.0	6
23	Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts. Journal of Visualized Experiments, 2020, , .	0.2	13
24	Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. Journal of Urology, 2020, 203, 120-127.	0.2	3
25	Racial Discrepancies in Overall Survival among Men Treated with ²²³ Radium. Journal of Urology, 2020, 203, 331-337.	0.2	25
26	Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2020, 204, 511-517.	0.2	9
27	Reply by Authors. Journal of Urology, 2020, 203, 127-127.	0.2	0
28	Predictors of skeletalâ€related events and mortality in men with metastatic, castrationâ€resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer, 2019, 125, 4003-4010.	2.0	15
29	Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. Clinical Genitourinary Cancer, 2019, 17, e930-e938.	0.9	1
30	Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 633-635.	2.0	13
31	Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer. European Urology Oncology, 2019, 2, 584-588.	2.6	10
32	Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 289.e11-289.e17.	0.8	16
33	First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes and Control, 2019, 30, 259-269.	0.8	3
34	Association of Black Race With Prostate Cancerâ€“Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	3.4	288
35	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. Journal of Clinical Oncology, 2019, 37, 2062-2071.	0.8	80
36	Association of Treatment With 5Î±-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. JAMA Internal Medicine, 2019, 179, 812.	2.6	44

#	Article	IF	Citations
37	Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer, 2019, 125, 3025-3032.	2.0	3
38	Poorly controlled diabetes increases the risk of metastases and castrationâ€resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer, 2019, 125, 2861-2867.	2.0	20
39	Practice patterns and outcomes of equivocalÂbone scans for patients with castration-resistant prostate cancer: ResultsÂfrom SEARCH. Asian Journal of Urology, 2019, 6, 242-248.	0.5	3
40	Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1068-1076.	0.4	6
41	Does race predict the development of metastases in men who receive androgenâ€deprivation therapy for a biochemical recurrence after radical prostatectomy?. Cancer, 2019, 125, 434-441.	2.0	3
42	Obesity, risk of biochemical recurrence, and prostateâ€specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU International, 2019, 124, 69-75.	1.3	15
43	Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clinical Genitourinary Cancer, 2019, 17, e140-e149.	0.9	7
44	Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 252-260.	2.0	24
45	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. Clinical Genitourinary Cancer, 2019, 17, e505-e512.	0.9	24
46	Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) database. BJU International, 2018, 122, 592-598.	1.3	9
47	Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1188-1193.	0.4	18
48	Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes and Control, 2018, 29, 581-588.	0.8	30
49	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e17-239.e25.	0.8	12
50	Threeâ€month posttreatment prostateâ€specific antigen level as a biomarker of treatment response in patients with intermediateâ€risk or highâ€risk prostate cancer treated with androgen deprivation therapy and radiotherapy. Cancer, 2018, 124, 2939-2947.	2.0	15
51	Obese patients with castrationâ€resistant prostate cancer may be at a lower risk of allâ€cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2018, 122, 76-82.	1.3	15
52	Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. Journal of Urology, 2018, 199, 53-59.	0.2	44
53	Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. Journal of Urology, 2018, 199, 713-718.	0.2	7
54	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	0.8	162

#	Article	IF	Citations
55	Impact of prior local therapy on overall survival in men with metastatic castrationâ€resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. International Journal of Urology, 2018, 25, 998-1004.	0.5	13
56	Nerve-targeted probes for fluorescence-guided intraoperative imaging. Theranostics, 2018, 8, 4226-4237.	4.6	51
57	Fluorescence-Based Molecular Imaging of Porcine Urinary Bladder Sentinel Lymph Nodes. Journal of Nuclear Medicine, 2017, 58, 547-553.	2.8	24
58	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	0.9	79
59	Characterization of a â€œlowâ€riskâ€•cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2017, 24, 611-617.	0.5	3
60	Thresholds for <scp>PSA</scp> doubling time in men with nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2017, 120, E80-E86.	1.3	46
61	Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Stratification: A Systematic Review. European Urology Focus, 2017, 3, 487-497.	1.6	46
62	Factors predicting skeletalâ€related events in patients with bone metastatic castrationâ€resistant prostate cancer. Cancer, 2017, 123, 1528-1535.	2.0	22
63	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate, 2017, 77, 1592-1600.	1.2	8
64	Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology, 2017, 108, 129-134.	0.5	17
65	Predictors of operative time during radical retropubic prostatectomy and robotâ€assisted laparoscopic prostatectomy. International Journal of Urology, 2017, 24, 618-623.	0.5	16
66	Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. Journal of Urology, 2017, 198, 1309-1315.	0.2	15
67	Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer, 2017, 123, 4199-4206.	2.0	30
68	Validation of the 2015 prostate cancer grade groups for predicting longâ€term oncologic outcomes in a shared equalâ€access health system. Cancer, 2017, 123, 4122-4129.	2.0	15
69	Number of Unfavorable Intermediateâ€Risk Factors Predicts Pathologic Upstaging and Prostate Cancerâ€Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate, 2017, 77, 154-163.	1.2	22
70	Weight Loss Following Radical Cystectomy forÂBladder Cancer: Characterization and EffectÂonÂSurvival. Clinical Genitourinary Cancer, 2017, 15, 86-92.	0.9	14
71	In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. European Urology Focus, 2017, 3, 480-486.	1.6	11
72	Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 2017, 15, 60-66.e2.	0.9	79

#	Article	IF	Citations
73	Robotic Pelvic Lymphadenectomy: Standard and Extended Techniques. , 2017, , 323-330.		0
74	Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Research and Reports in Urology, 2016, Volume 8, 77-84.	0.6	16
75	Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2016, 23, 241-246.	0.5	2
76	Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal of Urology, 2016, 196, 1408-1414.	0.2	43
77	Is computed tomography a necessary part of a metastatic evaluation for castrationâ€resistant prostate cancer? Results from <scp>the Shared Equal Access Regional Cancer Hospital Database</scp>. Cancer, 2016, 122, 222-229.	2.0	6
78	Validation of a bone scan positivity risk table in nonâ€metastatic castrationâ€resistant prostate cancer. BJU International, 2016, 118, 570-577.	1.3	8
79	Do all men with pathological Gleason score 8â€“10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	1.3	12
80	Adverse pathology and undetectable ultrasensitive prostateâ€specific antigen after radical prostatectomy: is adjuvant radiation warranted?. BJU International, 2016, 117, 897-903.	1.3	7
81	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
82	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 547-554.	1.1	15
83	Race does not predict the development of metastases in men with nonmetastatic castrationâ€resistant prostate cancer. Cancer, 2016, 122, 3848-3855.	2.0	8
84	Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. Asian Journal of Urology, 2016, 3, 229-239.	0.5	6
85	Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. BJU International, 2016, 118, 927-934.	1.3	7
86	Voxel Level Radiologicâ€“Pathologic Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2668-2674.	3.2	19
87	Positive surgical margins in radical prostatectomy patients do not predict longâ€term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (<scp>SEARCH</scp>) cohort. BJU International, 2016, 117, 244-248.	1.3	20
88	Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?. Urology, 2016, 93, 60-67.	0.5	11
89	Restriction spectrum imaging improves MRI-based prostate cancer detection. Abdominal Radiology, 2016, 41, 946-953.	1.0	20
90	Nerve-sparing Technique During Radical Prostatectomy and its Effect on Urinary Continence. European Urology, 2016, 69, 590-591.	0.9	6

#	Article	IF	Citations
91	Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancerâ€"Results from the SEARCH database. Cancer Epidemiology, 2015, 39, 1066-1070.	0.8	0
92	A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy. Scientific Reports, 2015, 5, 10544.	1.6	9
93	Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 658-662.	0.5	10
94	Is clinical stage T2c prostate cancer an intermediateâ€•or highâ€risk disease?. Cancer, 2015, 121, 1414-1421.	2.0	12
95	Prostate diffusion imaging with distortion correction. Magnetic Resonance Imaging, 2015, 33, 1178-1181.	1.0	29
96	Agent Orange and long-term outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e1-329.e6.	0.8	5
97	MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Frontiers in Oncology, 2015, 5, 30.	1.3	20
98	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature, 2015, 521, 94-98.	13.7	451
99	Virtual reality suturing task as an objective test for robotic experience assessment. BMC Urology, 2015, 15, 63.	0.6	8
100	Prostateâ€specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2015, 22, 362-366.	0.5	12
101	Practice Patterns and Predictors of Followup Imaging after a Negative Bone Scan in Men with Castration Resistant Prostate Cancer: Results from the SEARCH Database. Journal of Urology, 2015, 193, 1232-1238.	0.2	11
102	Impact of Family History on Prostate Cancer Mortality in White Men Undergoing Prostate Specific Antigen Based Screening. Journal of Urology, 2015, 193, 75-79.	0.2	40
103	What is the Incidence of Kidney Stones after Chemotherapy in Patients with Lymphoproliferative or Myeloproliferative Disorders?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 772-780.	0.7	3
104	Impact of renal surgery for cortical neoplasms on lipid metabolism. BJU International, 2014, 114, 837-843.	1.3	7
105	The impact of pathologic staging on the longâ€term oncologic outcomes of patients with clinically highâ€risk prostate cancer. Cancer, 2014, 120, 1656-1662.	2.0	24
106	Tumor infiltrating B-cells are increased in prostate cancer tissue. Journal of Translational Medicine, 2014, 12, 30.	1.8	137
107	Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the <scp>S</scp>hared <scp>E</scp>qual <scp>A</scp>ccess <scp>R</scp>egional <scp>C</scp>ancer <scp>H</scp>ospital (<scp>SEARCH</scp>) database. BJU International, 2014, 114, 661-666.	1.3	46
108	Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castrationâ€resistant prostate cancer, and mortality after radical prostatectomy. Cancer, 2014, 120, 197-204.	2.0	69

#	Article	IF	Citations
109	How to Minimize Lymphoceles and Treat Clinically Symptomatic Lymphoceles After Radical Prostatectomy. Current Urology Reports, 2014, 15, 445.	1.0	38
110	Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging. Cancer Research, 2014, 74, 4638-4652.	0.4	179
111	Minimally Invasive Cystectomy Is Associated With Improved Perioperative Patient Safety Outcomes Compared With Open Cystectomy in a National Cohort. Urology, 2014, 84, 314-320.	0.5	18
112	Reply. Urology, 2014, 84, 319-320.	0.5	0
113	Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2349-2356.	1.1	111
114	Preclinical Evaluation of Robotic-Assisted Sentinel Lymph Node Fluorescence Imaging. Journal of Nuclear Medicine, 2014, 55, 1552-1556.	2.8	13
115	Robotic-assisted Fluorescence Sentinel Lymph Node Mapping Using Multimodal Image Guidance in an Animal Model. Urology, 2014, 84, 982.e9-982.e14.	0.5	18
116	Detectable Prostate-Specific Antigen Nadir During Androgen-Deprivation Therapy Predicts Adverse Prostate Cancerâ€“Specific Outcomes: Results from the SEARCH Database. European Urology, 2014, 65, 620-627.	0.9	23
117	Editorial Comment. Urology, 2014, 83, 1367-1368.	0.5	1
118	Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy. European Urology, 2014, 65, 1171-1177.	0.9	110
119	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	2.3	294
120	Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis. BJU International, 2013, 111, E98-102.	1.3	12
121	Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy. World Journal of Urology, 2013, 31, 481-488.	1.2	69
122	Editorial Comment from <scp>D</scp>r <scp>L</scp>iss and <scp>D</scp>r <scp>K</scp>ane to Lymphocele after extraperitoneal robotâ€assisted radical prostatectomy: A propensity scoreâ€matching study. International Journal of Urology, 2013, 20, 1177-1177.	0.5	0
123	Do Nomograms Designed to Predict Biochemical Recurrence (BCR) Do a Better Job of Predicting More Clinically Relevant Prostate Cancer Outcomes than BCR? A Report from the SEARCH Database Group. Urology, 2013, 82, 53-59.	0.5	18
124	Comparison of Transrectal and Transvaginal Hybrid Natural Orifice Transluminal Endoscopic Surgery Partial Nephrectomy in the Porcine Model. Urology, 2013, 82, 84-89.	0.5	14
125	Does Timing of Cytoreductive Nephrectomy Impact Patient Survival With Metastatic Renal Cell Carcinoma in the Tyrosine Kinase Inhibitor Era? A Multi-institutional Study. Urology, 2013, 81, 805-812.	0.5	37
126	Delayed radical prostatectomy for intermediateâ€risk prostate cancer is associated with biochemical recurrence: Possible implications for active surveillance from the SEARCH database. Prostate, 2013, 73, 409-417.	1.2	75

#	Article	IF	Citations
127	Risk versus benefit of lymph node dissection during prostatectomy. Nature Reviews Urology, 2013, 10, 262-263.	1.9	0
128	Optimization via specific fluorescence brightness of a receptor-targeted probe for optical imaging and positron emission tomography of sentinel lymph nodes. Journal of Biomedical Optics, 2013, 18, 101315.	1.4	26
129	Diabetes predicts metastasis after radical prostatectomy in obese men: results from the <scp>SEARCH</scp> database. BJU International, 2013, 111, E310-8.	1.3	11
130	Initial Experience with Aspirin Use During Robotic Radical Prostatectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2012, 22, 225-229.	0.5	15
131	A Receptor-targeted Fluorescent Radiopharmaceutical for Multireporter Sentinel Lymph Node Imaging. Radiology, 2012, 265, 186-193.	3.6	62
132	Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. European Urology, 2012, 62, 910-916.	0.9	33
133	Does Salvage Radiation Therapy Change the Biology of Recurrent Prostate Cancer Based on PSA Doubling Times? Results from the SEARCH Database. Urology, 2012, 79, 1105-1110.	0.5	1
134	Feasibility of Transrectal Hybrid Natural Orifice Transluminal Endoscopic Surgery (NOTES) Nephrectomy in the Cadaveric Model. Urology, 2012, 80, 590-595.	0.5	15
135	Preoperative sentinel lymph node mapping of the prostate using PET/CT fusion imaging and Ga-68-labeled tilmanocept in an animal model. Clinical and Experimental Metastasis, 2012, 29, 673-680.	1.7	29
136	Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equalâ€access health care setting. Cancer, 2012, 118, 4999-5007.	2.0	49
137	Comparison of rates and risk factors for development of anaemia and erythropoiesisâ€stimulating agent utilization after radical or partial nephrectomy. BJU International, 2012, 109, 1019-1025.	1.3	22
138	Obesity is associated with castrationâ€resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU International, 2012, 110, 492-498.	1.3	82
139	Management of pelvic lymphoceles following robot-assisted laparoscopic radical prostatectomy. Urology Annals, 2012, 4, 111.	0.3	22
140	Does salvage radiation therapy (SRT) change the biology of recurrent prostate cancer (PCa) based on PSA doubling timesÂ(PSADT)?ÂResults from the SEARCH database.. Journal of Clinical Oncology, 2012, 30, 203-203.	0.8	0
141	Robotic prostatectomy improves outcomes–after the potentially risky adoption phase. Oncology, 2012, 26, 626, 628, 630.	0.4	0
142	What Do I Tell Patients About Saw Palmetto for Benign Prostatic Hyperplasia?. Urologic Clinics of North America, 2011, 38, 261-277.	0.8	11
143	Does PSADT After Radical Prostatectomy Correlate With Overall Survival?â€"A Report From the SEARCH Database Group. Urology, 2011, 77, 149-153.	0.5	16
144	Comparison of Rates and Risk Factors for Development of Osteoporosis and Fractures After Radical or Partial Nephrectomy. Urology, 2011, 78, 614-619.	0.5	29

#	Article	IF	Citations
145	Treatment Trends for Stage I Renal Cell Carcinoma. Journal of Urology, 2011, 186, 394-399.	0.2	95
146	A natural history of weight change in men with prostate cancer on androgenâ€deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2011, 107, 924-928.	1.3	37
147	A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. Journal of Translational Medicine, 2011, 9, 185.	1.8	34
148	Robotic-Assisted Laparoscopic Prostatectomy for High-Risk Prostate Cancer: Technical Considerations and Review of the Literature. ISRN Urology, 2011, 2011, 1-7.	1.5	4
149	Reâ€calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU International, 2010, 105, 1654-1659.	1.3	10
150	Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer, 2010, 116, 3389-3398.	2.0	112
151	Glycemic control and prostate cancer progression: Results from the SEARCH database. Prostate, 2010, 70, 1540-1546.	1.2	42
152	Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU International, 2010, 105, 28-33.	1.3	21
153	Adequacy of lymphadenectomy among men undergoing robotâ€assisted laparoscopic radical prostatectomy. BJU International, 2010, 105, 88-92.	1.3	53
154	Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU International, 2010, 105, 347-351.	1.3	12
155	Definition and preoperative predictors of persistently elevated prostateâ€specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU International, 2010, 105, 1541-1547.	1.3	20
156	Feasibility and efficacy of neoadjuvant sunitinib before nephronâ€sparing surgery. BJU International, 2010, 106, 1270-1276.	1.3	86
157	Postoperative prostateâ€specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. International Journal of Urology, 2010, 17, 914-922.	0.5	9
158	Laparo-Endoscopic Single-Site Surgery for Radical and Cytoreductive Nephrectomy, Renal Vein Thrombectomy, and Partial Nephrectomy: A Prospective Pilot Evaluation. Diagnostic and Therapeutic Endoscopy, 2010, 2010, 1-8.	1.5	9
159	Diabetes and Outcomes After Radical Prostatectomy: Are Results Affected by Obesity and Race? Results from the Shared Equal-Access Regional Cancer Hospital Database. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 9-17.	1.1	42
160	Freedom From a Detectable Ultrasensitive Prostate-specific Antigen at Two Years After Radical Prostatectomy Predicts a Favorable Clinical Outcome: Analysis of the SEARCH Database. Urology, 2010, 75, 439-444.	0.5	20
161	Outcomes After Radical Prostatectomy Among Men Who Are Candidates for Active Surveillance: Results From the SEARCH Database. Urology, 2010, 76, 695-700.	0.5	75
162	Association of Cigarette Smoking With Interval to Biochemical Recurrence After Radical Prostatectomy: Results from the SEARCH Database. Urology, 2010, 76, 1218-1223.	0.5	28

#	Article	IF	Citations
163	Race and Time from Diagnosis to Radical Prostatectomy: Does Equal Access Mean Equal Timely Access to the Operating Room?â€"Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1208-1212.	1.1	24
164	Obesity as a predictor of adverse outcome across black and white race. Cancer, 2009, 115, 5263-5271.	2.0	66
165	Watchful waiting versus active surveillance: Appropriate patient selection. Current Prostate Reports, 2009, 7, 5-10.	0.1	0
166	Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?. BJU International, 2009, 103, 603-608.	1.3	21
167	Exposure to Agent Orange is a significant predictor of prostateâ€specific antigen (PSA)â€based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU International, 2009, 103, 1168-1172.	1.3	18
168	Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU International, 2009, 104, 1452-1456.	1.3	38
169	Does early prostateâ€specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU International, 2009, 104, 1604-1609.	1.3	17
170	Natural History of Persistently Elevated Prostate Specific Antigen After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2009, 182, 2250-2256.	0.2	47
171	Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy. Journal of Urology, 2009, 182, 491-498.	0.2	18
172	Watchful waiting versus active surveillance: Appropriate patient selection. Current Urology Reports, 2008, 9, 211-216.	1.0	10
173	Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer, 2008, 112, 2664-2670.	2.0	361
174	Renal cell cancer stage migration. Cancer, 2008, 113, 78-83.	2.0	535
175	Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU International, 2008, 102, 964-968.	1.3	44
176	Obesity and oncological outcome after radical prostatectomy: impact of prostateâ€specific antigenâ€based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center Databases. BJU International, 2008, 102, 969-974.	1.3	49
177	The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU International, 2008, 102, 1074-1079.	1.3	29
178	PSA in the New Millennium: A Powerful Predictor of Prostate Cancer Prognosis and Radical Prostatectomy Outcomes â€" Results from the SEARCH Database. European Urology, 2008, 53, 758-766.	0.9	34
179	The Effect of Race/Ethnicity on the Accuracy of the 2001 Partin Tables for Predicting Pathologic Stage of Localized Prostate Cancer. Urology, 2008, 71, 151-155.	0.5	14
180	Effect of BMI on Primary Treatment of Prostate Cancer. Urology, 2008, 72, 406-411.	0.5	27

#	Article	IF	Citations
181	What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? A Report From the SEARCH Database Group. Journal of Urology, 2008, 180, 1980-1985.	0.2	19
182	Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2008, 179, 1785-1790.	0.2	17
183	Is a Positive Bladder Neck Margin Truly a T4 Lesion in the Prostate Specific Antigen Era? Results From the SEARCH Database. Journal of Urology, 2008, 179, 124-129.	0.2	18
184	Effects of Hospital Procedure Volume and Resident Training on Clinical Outcomes and Resource Use in Radical Retropubic Prostatectomy Surgery in the Department of Veterans Affairs. Journal of Urology, 2008, 179, 272-279.	0.2	23
185	Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2008, 179, 1791-1796.	0.2	32
186	Small Transrectal Ultrasound Volume Predicts Clinically Significant Gleason Score Upgrading After Radical Prostatectomy: Results From the SEARCH Database. Journal of Urology, 2008, 179, 523-528.	0.2	60
187	Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. JAMA - Journal of the American Medical Association, 2007, 298, 2275.	3.8	291
188	Upgrading and Downgrading of Prostate Needle Biopsy Specimens: Risk Factors and Clinical Implications. Urology, 2007, 69, 495-499.	0.5	158
189	Optimal Timing, Cutoff, and Method of Calculation of Preoperative Prostate-Specific Antigen Velocity to Predict Relapse After Prostatectomy: A Report from SEARCH. Urology, 2007, 69, 732-737.	0.5	24
190	Impact of Obesity on the Utility of Preoperative Prostate-Specific Antigen Velocity to Predict for Relapse After Prostatectomy: A Report from the SEARCH Database. Urology, 2007, 69, 921-926.	0.5	9
191	Do Racial Differences in Prostate Size Explain Higher Serum Prostate-Specific Antigen Concentrations Among Black Men?. Urology, 2007, 69, 1138-1142.	0.5	19
192	Risk Stratification of Men with Gleason Score 7 to 10 Tumors by Primary and Secondary Gleason Score: Results from the SEARCH Database. Urology, 2007, 70, 277-282.	0.5	46
193	Body Mass Index, Prostate Weight and Transrectal Ultrasound Prostate Volume Accuracy. Journal of Urology, 2007, 178, 990-995.	0.2	30
194	Predicting Unilateral Prostate Cancer Based on Biopsy Features: Implications for Focal Ablative Therapyâ€"Results From the SEARCH Database. Journal of Urology, 2007, 178, 1249-1252.	0.2	55
195	Changing Nature of High Risk Patients Undergoing Radical Prostatectomy. Journal of Urology, 2007, 177, 113-117.	0.2	67
196	Education predicts quality of life among men with prostate cancer cared for in the department of Veterans affairs. Cancer, 2007, 109, 1769-1776.	2.0	53
197	Race, biochemical disease recurrence, and prostateâ€"specific antigen doubling time after radical prostatectomy. Cancer, 2007, 110, 2202-2209.	2.0	62
198	Conservative Management of Ureteral Calculi. , 2007, , 457-464.		1

#	Article	IF	Citations
199	Delay of Radical Prostatectomy and Risk of Biochemical Progression in Men With Low Risk Prostate Cancer. Journal of Urology, 2006, 175, 1298-1303.	0.2	75
200	Prostate Biopsy Tumor Extent but Not Location Predicts Recurrence After Radical Prostatectomy: Results From CaPSURE. Journal of Urology, 2006, 175, 125-129.	0.2	21
201	Is Biopsy Gleason Score Independently Associated With Biochemical Progression Following Radical Prostatectomy After Adjusting for Pathological Gleason Score?. Journal of Urology, 2006, 176, 2453-2458.	0.2	28
202	Obesity, Serum Prostate Specific Antigen and Prostate Size: Implications for Prostate Cancer Detection. Journal of Urology, 2006, 175, 500-504.	0.2	156
203	Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE. Urology, 2006, 68, 1242-1247.	0.5	19
204	Laparoscopic Approaches to Renal Malignancies. Current Problems in Cancer, 2006, 30, 168-193.	1.0	1
205	Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer, 2006, 106, 79-86.	2.0	61
206	Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer, 2006, 107, 1265-1272.	2.0	102
207	Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006, 107, 2384-2391.	2.0	129
208	Laparoscopic versus Open Cytoreductive Nephrectomy in Advanced Renal-Cell Carcinoma. Journal of Endourology, 2006, 20, 504-508.	1.1	33
209	The effect of kidney morcellation on operative time, incision complications, and postoperative analgesia after laparoscopic nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2006, 32, 273-280.	0.7	14
210	Ethnic group-related differences in CpG hypermethylation of theGSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. International Journal of Cancer, 2005, 116, 174-181.	2.3	88
211	Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study. Journal of Clinical Oncology, 2005, 23, 7546-7554.	0.8	213
212	Multigene Methylation Analysis for Detection and Staging of Prostate Cancer. Clinical Cancer Research, 2005, 11, 6582-6588.	3.2	106
213	Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 7735-7742.	3.2	1
214	ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 1126-1131.	0.2	69
215	OBESITY AND PROSTATE CANCER CLINICAL RISK FACTORS AT PRESENTATION: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 732-736.	0.2	53
216	THE IMPACT OF OBESITY ON HEALTH RELATED QUALITY OF LIFE BEFORE AND AFTER RADICAL PROSTATECTOMY (DATA FROM CaPSURE). Journal of Urology, 2005, 173, 1132-1138.	0.2	62

#	Article	IF	Citations
217	Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology, 2005, 66, 1060-1065.	0.5	135
218	CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer. Cancer Research, 2004, 64, 5956-5962.	0.4	85
219	Impact of Obesity on Biochemical Control After Radical Prostatectomy for Clinically Localized Prostate Cancer: A Report by the Shared Equal Access Regional Cancer Hospital Database Study Group. Journal of Clinical Oncology, 2004, 22, 446-453.	0.8	366
220	Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer, 2004, 100, 1633-1638.	2.0	40
221	Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer, 2004, 101, 748-753.	2.0	24
222	OBESITY AND BIOCHEMICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY FOR ORGAN CONFINED DISEASE WITH NEGATIVE SURGICAL MARGINS. Journal of Urology, 2004, 172, 520-524.	0.2	89
223	DIFFERENCES IN COMPLICATIONS AND OUTCOMES FOR OBESE PATIENTS UNDERGOING LAPAROSCOPIC RADICAL, PARTIAL OR SIMPLE NEPHRECTOMY. Journal of Urology, 2004, 172, 2287-2291.	0.2	74
224	PREOPERATIVE MODEL FOR PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY USING PERCENT OF BIOPSY TISSUE WITH CANCER, BIOPSY GLEASON GRADE AND SERUM PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2004, 171, 2215-2220.	0.2	48
225	KIDNEY GENE DATABASE: A CURATED AND INTEGRATED DATABASE OF GENES INVOLVED IN KIDNEY DISEASE. Journal of Urology, 2004, 172, 2344-2346.	0.2	2
226	Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal functional outcomes. Urology, 2004, 63, 241-246.	0.5	60
227	Do younger men have better biochemical outcomes after radical prostatectomy?. Urology, 2004, 63, 518-522.	0.5	58
228	Update of staging and risk assessment for prostate cancer patients. Current Opinion in Urology, 2004, 14, 163-170.	0.9	11
229	The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy. Cancer, 2003, 98, 2344-2350.	2.0	45
230	Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system. International Journal of Radiation Oncology Biology Physics, 2003, 55, 964-969.	0.4	27
231	Sociodemographic and Clinical Risk Characteristics of Patients With Prostate Cancer Within the Veterans Affairs Health Care System: Data From CaPSURE. Journal of Urology, 2003, 170, 905-908.	0.2	38
232	Comparison of Preoperative Prostate Specific Antigen Density and Prostate Specific Antigen for Predicting Recurrence After Radical Prostatectomy: Results from the Search Data Base. Journal of Urology, 2003, 169, 969-973.	0.2	55
233	Percent of Prostate Needle Biopsy Cores With Cancer is Significant Independent Predictor of Prostate Specific Antigen Recurrence Following Radical Prostatectomy: Results From SEARCH Database. Journal of Urology, 2003, 169, 2136-2141.	0.2	95
234	Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology, 2003, 61, 607-611.	0.5	235

#	Article	IF	Citations
235	Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology, 2003, 61, 742-747.	0.5	61
236	Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology, 2003, 61, 736-741.	0.5	133
237	Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology, 2003, 62, 1035-1039.	0.5	40
238	Improved Clinical Staging System Combining Biopsy Laterality and TNM Stage for Men With T1c and T2 Prostate Cancer: Results From the SEARCH Database. Journal of Urology, 2003, 169, 2129-2135.	0.2	22
239	Should a Positive Surgical Margin Following Radical Prostatectomy be Pathological Stage T2 or T3? Results From the SEARCH Database. Journal of Urology, 2003, 169, 2142-2146.	0.2	58
240	PGDB: a curated and integrated database of genes related to the prostate. Nucleic Acids Research, 2003, 31, 291-293.	6.5	50
241	Effect of Race on Biochemical Disease-free Outcome in Patients with Prostate Cancer Treated with Definitive Radiation Therapy in an Equal-Access Health Care System: Radiation Oncology Report of the Department of Defense Center for Prostate Disease Research. Radiology, 2002, 225, 420-426.	3.6	29
242	Prospective Comparison of Computerized Tomography and Excretory Urography in the Initial Evaluation of Asymptomatic Microhematuria. Journal of Urology, 2002, 168, 2457-2460.	0.2	126
243	Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology, 2002, 60, 670-674.	0.5	100
244	Prospective Comparison of Computerized Tomography and Excretory Urography in the Initial Evaluation of Asymptomatic Microhematuria. Journal of Urology, 2002, , 2457-2460.	0.2	8
245	Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology, 2001, 58, 723-728.	0.5	122
246	THE ROLE OF IMAGING STUDIES AND MOLECULAR MARKERS FOR SELECTING CANDIDATES FOR RADICAL PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 459-472.	0.8	30
247	Unenhanced helical computed tomography in the evaluation of acute flank pain. Current Opinion in Urology, 2000, 10, 123-129.	0.9	25
248	Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology, 2000, 56, 1016-1020.	0.5	89
249	CURRENT MANAGEMENT OF SEVERELY ENCRUSTED URETERAL STENTS WITH A LARGE ASSOCIATED STONE BURDEN. Journal of Urology, 2000, 164, 648-650.	0.2	119
250	TIME TO STONE PASSAGE FOR OBSERVED URETERAL CALCULI: A GUIDE FOR PATIENT EDUCATION. Journal of Urology, 1999, 162, 688-691.	0.2	394
251	Drug-seeking behavior in urolithiasis in the noncontrast computed tomography era: 2 cases. Urology, 1999, 54, 744.	0.5	10
252	RE: METASTATIC ADENOCARCINOMA OF THE PROSTATE TO THE CHOROID WITH LOSS OF VISUAL ACUITY AS A PRESENTING SYMPTOM. Journal of Urology, 1999, 162, 809-809.	0.2	0

#	Article	IF	Citations
253	LIMITED VALUE OF BONE SCINTIGRAPHY AND COMPUTED TOMOGRAPHY IN ASSESSING BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 1999, , 176.	0.2	4
254	Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain. Urology, 1998, 52, 982-987.	0.5	210
255	SECOND PRIMARY MALIGNANCIES IN T1-3N0 PROSTATE CANCER PATIENTS TREATED WITH RADIATION THERAPY WITH 10-YEAR FOLLOWUP. Journal of Urology, 1998, 159, 946-949.	0.2	42
256	Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 1997, 3, 108-112.	0.8	53
257	Adenocarcinoma of the prostate metastatic to the choroid of the eye. Prostate, 1995, 27, 336-339.	1.2	10
258	Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urology Practice, 0, , .	0.2	0